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Medical care in many industrialized counties became a part of essential infrastructure of societies either under public medical care system, like most of EU countries, Canada and Japan, or being covered by major private insurance companies, typically in The United States. Most of the data in such systems are digitalized in these days, including diagnosis, medical test results and transaction of expenses of every patient. It would therefore be easier than before to analyze these data to explore public health needs, examine cost-benefit balance and search marketing potential for drugs and medical devices if they are available and accessible. However, health care systems themselves may be reluctant to release these "raw" data freely for many reasons. Consequently, some private industries may start business to make those data commercially available based on contract with certain particular medical institutions. Medical Data Vision (MDV) Co. Ltd. is one of those companies, who collects the data of the claims to Japanese public medical insurance systems from some 300 acute-care hospitals being uncoupled with patient identification and provides them on commercial basis.
Teramoto and his colleagues including investigators from Sanofi pharmaceutical company analyzed the data provided by MDV to examine the trend in treatment of the patients with elevated plasma LDL level in Japan 1) . They intended to focus on familial hypercholesterolemia (FH) to evaluate about how the patients are identified, diagnosed and treated in general practice. Among nearly 8 million patient data available, 77,415 patients were found 20 years-old or higher with LDL cholesterol measured enough to estimate the 2-year baseline, and 3,495 patients were identified as study population defined either as FHdiagnosed (FH-D) to whom FH diagnosis was given by an attending physician (193) or as FH-suspected (FH-S) whose LDL-cholesterol was 190 mg/dL or higher at least once in 2 years (3302). The authors analyzed the treatment given to these patients and concluded that FH is underdiagnosed and undertreated in Japan. The data are interesting and worthwhile publishing as we may see how high-LDL patients are "diagnosed" and treated in practice under the Japanese health care system. However, there are some issues the readers should be careful about when reading these data.
The authors discuss about the rate of diagnosis of FH and say it is underestimated in Japan referring to its prevalence in Japan estimated by Mabuchi et al.
2)
based on the analysis of the patients in Hokuriku area. However, the authors in this reference themselves suggested that the estimated prevalence of FH, 1/208, potentially includes founders effect in the area because one particular type of mutation accounts for as much as around 30% in this region while it is only 3% in Osaka area 3) . Therefore, this number may be overestimation for general population. The prevalence of FH-D 1/401 in the data analyzed by Teramoto et al. may rather represent general prevalence of FH among Japanese. If so, FH was diagnosed nearly 100% as far as people were measured for plasma cholesterol in acutecare hospitals in Japan. On the other hand, screening of FH-S does not seem based on the JAS FH guideline. Elevation of LDL-cholesterol is merely one of the criteria for FH in the guideline. Bring up 10 -20 times more candidate subjects by screening is apparently overestimation. It may be inappropriate and mislead the audience to call them FH-S.
In addition, scientific credibility of the data in the claims to Japanese public medical insurance systems should also be questioned, especially the quality of diagnosis. The claims are submitted from medical facilities to ask reimbursement of their cost, which is strictly regulated by the national health insurance sys-What we should be afraid of is that using these types of database for "marketing research" of medical supplies may push the "market" further towards a wrong direction which may currently be already so.
